QLT reported its financial position for the full-year 2007. Visudyne(R) sales for the full year represented a decrease of 39.3% over annual sales in 2006; however, Eligard(R) sales increased almost 50% from the prior year.

Since the beginning of last year, QLT share price went down quarter by quarter. In November 2007, QLT disclosed its plans to sell all or part of its assets. At that time, the company beat records almost every day for having the lowest price.

In 2008, QLT plans to focus on its Visudyne(R), its photodynamic therapy  dermatology technology and its punctal plug delivery technology. The latter was acquired in October 2007 by the acquisition of ForSight Newco II.

More information on QLT company in DelScience's report: "Company profile: QLT, Inc.".

Source: QLT, Inc.